Mesalamine Suppository Low-Melting Base
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current mesalamine suppositories are large and have high melting points, leading to discomfort and potential issues with viscosity during manufacturing, which affects content uniformity and therapeutic efficacy.
Innovation Solution
Reducing the size of mesalamine suppositories by increasing the tap density and lowering the melting point of the suppository base, while maintaining therapeutic efficacy, by using a combination of mesalamine and a low-melting suppository base such as hard fat, to enhance comfort and uniformity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If the size of mesalamine suppository is reduced, then comfort of use is improved, but manufacturing precision deteriorates due to viscosity issues
Solution Approach 1:
The patent changes the physical parameters of the suppository base by selecting materials with lower melting points (e.g., glycerol monostearate, glycerol distearate, or their mixtures). This parameter change allows the formulation of smaller suppositories with reduced viscosity at processing temperatures, enabling both improved comfort of use and maintained manufacturing precision through better flow and filling characteristics
Solution Approach 2:
The patent employs composite suppository base formulations, specifically mixtures of glycerol monostearate and glycerol distearate in various ratios. These composite materials combine the advantages of both components to achieve optimal viscosity characteristics that facilitate manufacturing of smaller suppositories while ensuring content uniformity and therapeutic efficacy
2Ease of operation
If the melting point of suppository base is lowered, then comfort of use is improved, but manufacturing complexity increases
Solution Approach 1:
The patent systematically evaluates and selects suppository base materials based on their melting point parameters, choosing compounds with melting points below 40°C (such as glycerol monostearate at 38-40°C and glycerol distearate at 36-38°C). This parameter optimization ensures the suppositories are comfortable for rectal administration while maintaining straightforward manufacturing processes without requiring complex temperature control systems
3Reliability
If the drug load is increased, then therapeutic efficacy is improved, but viscosity increases making casting difficult
Solution Approach 1:
The patent optimizes the melting point parameter of the suppository base to be below 40°C, which ensures that even at high drug loads (40-60% w/w), the mixture maintains suitable viscosity for casting. The selected bases (glycerol monostearate, glycerol distearate, or their mixtures) provide a eutectic effect that prevents excessive viscosity increase, allowing high drug load formulations to be successfully cast into suppositories with good content uniformity
Solution Approach 2:
The patent uses composite base formulations of glycerol monostearate and glycerol distearate in optimized ratios to create a matrix that can accommodate high drug loads while maintaining workable viscosity. The synergistic interaction between these two esters creates a formulation system where high mesalamine content (40-60%) does not lead to unmanageable viscosity, enabling both therapeutic efficacy and ease of manufacturing
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution results in a smaller, more comfortable mesalamine suppository with improved dissolution profiles, releasing at least 75% of the drug within 2 hours, ensuring effective treatment of ulcerative colitis with reduced side effects and improved manufacturing processes.
Implementation Method 1
lowering the melting point of the suppository base
Data Source
AI summary
The present invention relates to a mesalamine rectal suppository designed to provide improved comfort of use. One embodiment of the invention is a mesalamine rectal suppository comprising mesalamine and one or more pharmaceutically acceptable excipients, wherein the drug load of the suppository ranges from 35% to 50%. Another embodiment of the invention is a mesalamine rectal suppository comprising from about 850 to about 1150 mg mesalamine and one or more pharmaceutically acceptable excipients, wherein the total weight of the suppository ranges from about 2250 to about 2700 mg. Another embodiment of the invention is a mesalamine rectal suppository comprising from about 400 to about 600 mg mesalamine and one or more pharmaceutically acceptable excipients, wherein the total weight of the suppository ranges from about 870 to about 1715 mg. Yet another embodiment of the invention is a mesalamine rectal suppository comprising mesalamine having a tap density ranging from about 600 to about 800 g/L (as measured by USP <616>) and a hard fat having an ascending melting point of 32 to 35.5° C. Methods of preparing and methods of treatment with mesalamine suppositories are also provided. The invention further provides a method of determining a dissolution parameter (such as dissolution rate) of a mesalamine rectal suppository, such as a 1 g mesalamine suppository, by measuring its dissolution with USP Apparatus #2 at 40° C. and a paddle rotation speed of 125 rpm in 0.2 M phosphate buffer at a pH of 7.5.